Top pharma executives get the chance to air their grievances during a once-a-year “meet the regulators” session in Beijing. In this second part of coverage of the meeting, China FDA director Wang Lifeng discusses marketing authorization holder pilots while CEOs including Betta’s Ding Lieming touch upon provincial tenders, orphan drugs and patent invalidity appeals.

A long-awaited new law that could greatly enlarge the market for traditional Chinese medicines has prompted domestic drug makers in China to race to develop new products, but could it also hurt multinational drug companies in the country?

A long-awaited law could greatly enlarge the traditional Chinese medicine market and has prompted drug makers in the country to race to develop TCM products. The potential TCM boom has multinational drug firms leaping into the fray, some to partner with locals and others establishing teams devoted to TCM R&D.

A long-awaited law could greatly enlarge the traditional Chinese medicine market and has prompted drug makers in the country to race to develop TCM products. The potential TCM boom has multinational drug firms leaping into the fray, some to partner with locals and others establishing teams devoted to TCM R&D.